Suppr超能文献

证据说话:低剂量预防的有效性。

Show me the evidence: Effectiveness of low-dose prophylaxis.

机构信息

Hemophilia Center, Aziza Othmana Hospital, University Tunis El Manar, Tunis, Tunisia.

出版信息

Haemophilia. 2020 Apr;26 Suppl 3:9-10. doi: 10.1111/hae.13892.

Abstract

Prophylaxis is the gold standard treatment for haemophilia but requires more amount of clotting factor concentrates, than on demand therapy. Low dose prophylaxis is an alternative for countries with limited resources. There are data of evidence showing the superiority of low-dose prophylaxis than episodic treatment. Studies from China, India, Tunisia, Thailand and Indonesia reported experiences with low dose prophylaxis using outcome assessment. These studies have shown the effectiveness of various protocols regimen with once, twice or thrice injection of 10-15 UI Kg-1 per injection. These protocols allow reduction of joint bleeds and at least delay of joint damages. There is not enough long-term data nowadays, but low dose prophylaxis is certainly better than on demand therapy and should be considered as a first step of prophylaxis in some countries but not the final goal.

摘要

预防是血友病的金标准治疗方法,但需要比按需治疗更多的凝血因子浓缩物。低剂量预防是资源有限国家的一种替代方法。有证据表明,低剂量预防优于偶发性治疗。来自中国、印度、突尼斯、泰国和印度尼西亚的研究报告了使用结果评估的低剂量预防经验。这些研究表明,各种方案方案的有效性,每次、两次或三次注射 10-15UI/kg-1,每次注射。这些方案可减少关节出血,至少延迟关节损伤。目前还没有足够的长期数据,但低剂量预防肯定比按需治疗好,应在某些国家被视为预防的第一步,但不是最终目标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验